Erratum: Determination of [11C]Rifampin Pharmacokinetics within Mycobacterium tuberculosis-Infected Mice by Using Dynamic Positron Emission Tomography Bioimaging (Antimicrobial Agents and Chemotherapy (2015) 59:9 (5768-5774) 10.1128/AAC.01146-15);Determination of [11C]rifampin pharmacokinetics within Mycobacterium tuberculosis-infected mice by using dynamic positron emission tomography bioimaging

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 9, 2015, Pages 5768-5774

  DeMarco, Vincent P ^a   Ordonez, Alvaro A ^a   Klunk, Mariah ^a   Prideaux, Brendan ^b   Wang, Hui ^c   Zhuo, Zhang ^c   Tonge, Peter J ^c   Dannals, Robert F ^a   Holt, Daniel P ^a   Lee, Carlton K K ^a   Weinstein, Edward A ^a   Dartois, Véronique ^b   Dooley, Kelly E ^a   Jain, Sanjay K ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 11; RIFAMPICIN; RIFAMPIN C 11; UNCLASSIFIED DRUG; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; LUNG PARENCHYMA; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUBERCULOSIS; ANIMAL; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; METABOLISM; MICROBIOLOGY; PATHOGENICITY;

ANIMALS; ANTITUBERCULAR AGENTS; FEMALE; MICE; MYCOBACTERIUM TUBERCULOSIS; POSITRON-EMISSION TOMOGRAPHY; RIFAMPIN; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUBERCULOSIS;

EID: 84940915231     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01368-19     Document Type: Erratum

References (46)

1. Iseman MD. 2002. Tuberculosis therapy: past, present and future. Eur Respir J Suppl 36:87s-94s.
2. Davies GR, Nuermberger EL 2008. Pharmacokinetics and pharmacody-namics in the development of anti-tuberculosis drugs. Tuberculosis 88(Suppl 1):S65-S74. http://dx.doi.org/10.1016/S1472-9792(08)70037-4.
3. Srivastava S, Gumbo T. 2011. In vitro and in vivo modeling of tuberculosis drugs and its impact on optimization of doses and regimens. Curr Pharm Des 17:2881-2888. http://dx.doi.org/10.2174/138161211797470192.
4. Muller M, dela Pena A, Derendorf H. 2004. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob Agents Chemother 48:1441-1453. http://dx.doi.org/10.1128/AAC.48.5.1441-1453.2004.
5. Langer O, Muller M. 2004. Methods to assess tissue-specific distribution and metabolism of drugs. Curr Drug Metab 5:463-481. http://dx.doi.org/10.2174/1389200043335379.
6. Pasipanodya JG, Srivastava S, Gumbo T. 2012. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis 55:169-177. http://dx.doi.org/10.1093/cid/cis353.
7. McKenzie C. 2011. Antibiotic dosing in critical illness. J Antimicrob Chemother 66(Suppl 2):ii25-31. http://dx.doi.org/10.1093/jac/dkq516.
8. Prideaux B, Dartois V, Staab D., Weiner DM, Goh A, Via LE, Barry C.E., III, Stoeckli M. 2011. High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions. Anal Chem 83:2112-2118. http://dx.doi.org/10.1021/ac1029049.
9. Pan H, Yan BS, Rojas M, Shebzukhov Y.V., Zhou H., Kobzik L, Higgins DE, Daly M.J., Bloom BR, Kramnik I. 2005. Ipr1 gene mediates innate immunity to tuberculosis. Nature 434:767-772. http://dx.doi.org/10.1038/nature03419.
10. Harper J, Skerry C, Davis S.L., Tasneen R., Weir M, Kramnik I, Bishai W.R., Pomper MG, Nuermberger EL, Jain SK. 2012. Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. J Infect Dis 205:595-602. http://dx.doi.org/10.1093/infdis/jir786.
11. Driver ER, Ryan GJ, Hoff D.R., Irwin SM, Basaraba RJ, Kramnik I, Lenaerts AJ 2012. Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother 56:3181-3195. http://dx.doi.org/10.1128/AAC.00217-12.
12. Tasneen R, Jain SK, Nuremberger E. 2014. Cavitary TB in C3HeB/FeJ mice, abstr 2047, p 75. Novel Ther Approaches Tuberculosis (C7), Keystone, CO, 30 March to 4 April 2014. Keystone Symposia on Molecular and Cellular Biology, Keystone, CO.
13. Ordonez AA, Pokkali S, DeMarco V.P., Klunk M., Mease RC, Foss CA, Pomper MG, Jain SK 2015. Radioiodinated DPA-713 imaging correlates with bactericidal activity of tuberculosis treatments in mice. Antimicrob Agents Chemother 59:642-649. http://dx.doi.org/10.1128/AAC.04180-14.
14. Davis SL, Nuermberger EL, Um P.K., Vidal C., Jedynak B, Pomper MG, Bishai W.R., Jain SK. 2009. Noninvasive pulmonary [18F]-2-fluorodeoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrob Agents Chemother 53:4879-4884. http://dx.doi.org/10.1128/AAC.00789-09.
15. Liu L, Xu Y, Shea C., Fowler JS, Hooker JM, Tonge PJ. 2010. Radiosynthesis and bioimaging of the tuberculosis chemotherapeutics isoniazid, rifampicin and pyrazinamide in baboons. J Med Chem 53:2882-2891. http://dx.doi.org/10.1021/jm901858n.
16. Weinstein EA, Liu L, Ordonez A.A., Wang H., Hooker JM, Tonge PJ, Jain SK. 2012. Noninvasive determination of 2-[18F]-fluoroisonicotinic acid hydrazide pharmacokinetics by positron emission tomography in Mycobacterium tuberculosis-infected mice. Antimicrob Agents Chemother 56: 6284-6290. http://dx.doi.org/10.1128/AAC.01644-12.
17. Ordonez AA, DeMarco VP, Klunk M.H., Pokkali S., Jain SK. 7 March 2015. Imaging chronic tuberculous lesions using sodium [18F]fluoride positron emission tomography in mice. Mol Imaging Biol http://dx.doi.org/10.1007/s11307-015-0836-6.
18. Weinstein EA, Ordonez AA, DeMarco V.P., Murawski AM, Pokkali S, MacDonald EM, Klunk M, Mease R.C., Pomper MG, Jain SK. 2014. Imaging Enterobacteriaceae infection in vivo with 18F-fluorodeoxysorbitol positron emission tomography. Sci Transl Med 6:259ra146. http://dx.doi.org/10.1126/scitranslmed.3009815.
19. Foss CA, Harper JS, Wang H, Pomper M.G., Jain SK. 2013. Noninvasive molecular imaging of tuberculosis-associated inflammation with radioiodinated DPA-713. J Infect Dis 208:2067-2074. http://dx.doi.org/10.1093/infdis/jit331.
20. Robichaud G, Garrard KP, Barry J.A., Muddiman DC. 2013. MSiReader: an open-source interface to view and analyze high resolving power MS imaging files on Matlab platform. J Am Soc Mass Spectrom 24:718-721. http://dx.doi.org/10.1007/s13361-013-0607-z.
21. Dooley KE, Nuermberger EL, Diacon AH 2013. Pipeline of drugs for related diseases: tuberculosis. Curr Opin HIV AIDS 8:579-585. http://dx.doi.org/10.1097/COH.0000000000000009.
22. Diacon AH, Patientia RF, Venter A, van Helden PD, Smith PJ, McIlleron H, Maritz JS, Donald PR 2007. Early bactericidal activity of highdose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother 51:2994-2996. http://dx.doi.org/10.1128/AAC.01474-06.
23. Jayaram R, Gaonkar S, Kaur P., Suresh BL, Mahesh BN, Jayashree R, Nandi V., Bharat S, Shandil RK, Kantharaj E, Balasubramanian V. 2003. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 47:2118-2124. http://dx.doi.org/10.1128/AAC.47.7.2118-2124.2003.
24. Rosenthal IM, Zhang M, Williams K.N., Peloquin CA, Tyagi S, Vernon AA, Bishai W.R., Chaisson RE, Grosset JH, Nuermberger EL. 2007. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 4:e344. http://dx.doi.org/10.1371/journal.pmed.0040344.
25. Mitnick CD, McGee B, Peloquin CA 2009. Tuberculosis pharmacotherapy: strategies to optimize patient care. Expert Opin Pharmacother 10: 381-401. http://dx.doi.org/10.1517/14656560802694564.
26. Dorman SE, Savic RM, Goldberg S, Stout J.E., Schluger N., Muzanyi G, Johnson JL, Nahid P, Hecker E.J., Heilig CM, Bozeman L, Feng PJ, Moro R.N., MacKenzie W., Dooley KE, Nuermberger EL, Vernon A, Weiner M. Tuberculosis Trials Consortium 2015. Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am J Respir Crit Care Med 191:333-343. http://dx.doi.org/10.1164/rccm.201410-1843OC.
27. Boeree M, Hoelscher M. 2015. High-dose rifampin, SQ109 and moxifloxacin for treating TB: the PanACEA MAMS-TB Trial, abstr 95LB, p132. Conf Retroviruses Opportunistic Infect, Seattle, WA.
28. Chigutsa E, Pasipanodya JG, Visser M.E., van Helden PD, Smith PJ, Sirgel FA, Gumbo T, McIlleron H. 2015. Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect intuberculosis. Antimicrob Agents Chemother 59:38-45. http://dx.doi.org/10.1128/AAC.03931-14.
29. Pasipanodya JG, McIlleron H, Burger A., Wash PA, Smith P, Gumbo T. 2013. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 208:1464-1473. http://dx.doi.org/10.1093/infdis/jit352.
30. Ruslami R, Ganiem AR, Dian S, Apriani L., Achmad TH, van der Ven AJ, Borm G, Aarnoutse RE, van Crevel R. 2013. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis 13:27-35. http://dx.doi.org/10.1016/S1473-3099(12)70264-5.
31. Be NA, Kim KS, Bishai W.R., Jain SK. 2009. Pathogenesis of central nervous system tuberculosis. Curr Mol Med 9:94-99. http://dx.doi.org/10.2174/156652409787581655.
32. Thwaites GE, Schoeman JF 2009. Update on tuberculosis of the central nervous system: pathogenesis, diagnosis, and treatment. Clin Chest Med 30:745-754. http://dx.doi.org/10.1016/j.ccm.2009.08.018.
33. Mayosi BM, Burgess LJ, Doubell AF 2005. Tuberculous pericarditis. Circulation 112:3608-3616. http://dx.doi.org/10.1161/CIRCULATIONAHA.105.543066.
34. Kjellsson MC, Via LE, Goh A, Weiner D., Low KM, Kern S, Pillai G, Barry C.E., III, Dartois V. 2012. Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrob Agents Chemother 56:446-457. http://dx.doi.org/10.1128/AAC.05208-11.
35. Donald PR. 2010. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis 90:279-292. http://dx.doi.org/10.1016/j.tube.2010.07.002.
36. Mahajan M, Rohatgi D, Talwar V., Patni SK, Mahajan P, Agarwal DS. 1997. Serum and cerebrospinal fluid concentrations of rifampicin at two dose levels in children with tuberculous meningitis. J Commun Dis 29: 269-274.
37. Higgins LJ, Pomper MG 2011. The evolution of imaging in cancer: current state and future challenges. Semin Oncol 38:3-15. http://dx.doi.org/10.1053/j.seminoncol.2010.11.010.
38. Sathekge M, Maes A, Kgomo M., Stoltz A, Van de Wiele C. 2011. Use of 18F-FDG PET to predict response to first-line tuberculostatics in HIV-associated tuberculosis. J Nucl Med 52:880-885. http://dx.doi.org/10.2967/jnumed.110.083709.
39. Heysell SK, Thomas TA, Sifri C.D., Rehm PK, Houpt ER. 2013. 18-Fluorodeoxyglucose positron emission tomography for tuberculosis diagnosis and management: a case series. BMC Pulm Med 13:14. http://dx.doi.org/10.1186/1471-2466-13-14.
40. Chen RY, Dodd LE, Lee M, Paripati P., Hammoud DA, Mountz JM, Jeon D, Zia N., Zahiri H, Coleman MT, Carroll M.W., Lee JD, Jeong YJ, Herscovitch P, Lahouar S., Tartakovsky M, Rosenthal A, Somaiyya S., Lee S, Goldfeder LC, Cai Y, Via LE, Park SK, Cho SN, Barry CE, III. 2014. PET/CT imaging correlates with treatment outcomeinpatients with multidrug-resistant tuberculosis. Sci Transl Med 6:265ra166. http://dx.doi.org/10.1126/scitranslmed.3009501.
41. Fischman AJ, Alpert NM, Rubin RH 2002. Pharmacokinetic imaging: a noninvasive method for determining drug distribution and action. Clin Pharmacokinet 41:581-602. http://dx.doi.org/10.2165/00003088-200241080-00003.
42. Halldin C, Gulyas B, Farde L. 2001. PET studies with carbon-11 radioligands in neuropsychopharmacological drug development. Curr Pharm Des 7:1907-1929. http://dx.doi.org/10.2174/1381612013396871.
43. Rudin M, Weissleder R. 2003. Molecular imaging in drug discovery and development. Nat Rev Drug Discov 2:123-131. http://dx.doi.org/10.1038/nrd1007.
44. Lappin G, Noveck R, Burt T. 2013. Microdosing and drug development: past, present and future. Expert Opin Drug Metab Toxicol 9:817-834. http://dx.doi.org/10.1517/17425255.2013.786042.
45. Wagner CC, Langer O. 2011. Approaches using molecular imaging technology - use of PET in clinical microdose studies. Adv Drug Deliv Rev 63:539-546. http://dx.doi.org/10.1016/j.addr.2010.09.011.
46. Oosterhuis B. 2010. Trends in microdosing and other exploratory human pharmacokinetic studies for early drug development. Bioanalysis 2:377-379. http://dx.doi.org/10.4155/bio.10.11.